The Conundrum Of Alzheimer’s Disease R&D
This article was originally published in Start Up
Alzheimer’s disease science is in disarray and the risk associated with developing disease-modifying agents has driven many players from the field. But venturesome biotechs are finding backers to support efforts to look for a way forward: we profile Alzheon Inc., Neurotrack Inc., Rodin Therapeutics Inc., and Tetra Discovery Partners LLC.
You may also be interested in...
Up-Front Deal Economics May Not Match Drugs’ Likelihood Of Approval
In earlier development phases, most of the therapeutic classes with higher approval rates tend on average to have the larger up-front alliance payments. But in Phase III, licensees are paying top dollar for candidates in areas with the lowest likelihoods of approval.
Rodin Thinks Selective HDAC2 Inhibition Will Prove Better Therapeutic Approach To Alzheimer’s
Epigenetics-focused company believes a selective HDAC2 inhibitor could provide a safe way to treat signs and symptoms of Alzheimer’s. Having raised $12.9 million in Series A funding, Rodin hopes to move from lead optimization to clinical development over the next 18 to 24 months.
FDA Review Of GE’s Vizamyl Shows Caution In The Face Of Alzheimer’s Disease Unknowns
Regulators approved the PET imaging agent for estimating neuritic plaque density in the brain despite the apparent limited clinical utility of the class.